Postnatal vasculogenesis mediated via endothelial progenitor cells (EPCs) contributes to re-endothelialization and augments neovascularization after ischemia and tissue injury, providing a novel therapeutic application. However, controversy exists with respect to the origin, identification, and contributions of the EPCs to neovascularization, necessitating further study.
Recent Advances:
Bone marrow (BM) or circulating cells expressing cd133/vascular endothelial growth factor receptor 2 include those with endothelial progenitor capacity. Increasing evidence suggests that there are additional BM-derived (myeloid; mesenchymal cells) and non-BM-derived (peripheral and cord-blood; tissue-resident) cell populations which also give rise to endothelial cells (ECs) and contribute to re-endothelialization and growth factor release after ischemia and tissue injury. Currently, EPCs are being used as diagnostic markers for the assessment of cardiovascular and tumor risk/progression. Techniques aimed at enhancing ex vivo expansion and the therapeutic potential of these cells are being optimized.
Critical Issues:
Mobilization and EPC-mediated neovascularization are critically regulated. Stimulatory (growth factors, statins, and exercise) or inhibitory factors (obesity, diabetes, and other cardiovascular diseases) modulate EPC numbers and function. Recruitment and incorporation of EPCs require a coordinated sequence of signaling events, including adhesion, migration (by integrins), and chemoattraction. Finally, EPCs differentiate into ECs and/or secrete angiogenic growth factors. These cells are highly plastic, and depending on the microenvironment and presence of other cells, EPCs transdifferentiate and/or undergo cell fusion and become cells of a different lineage. Therefore, in vitro culture conditions should be optimized to mimic the in vivo milieu to fully characterize the biological function and contribution of EPCs to postnatal vasculogenesis.
Future Directions:
Advances in characterization of the EPC biology and enhancement of EPC functions are required. In addition, innovative tissue-engineered carrier matrices that permit embedding of EPCs and provide optimal conditions for EPC survival and endothelial outgrowth will further contribute to EPC-mediated therapeutic applications in wound healing and ischemia repair.
Get full access to this article
View all access options for this article.
References
1.
KoSH, NautaA, WongV, GlotzbachJ, GurtnerGC, LongakerMT. The role of stem cells in cutaneous wound healing: what do we really know?Plast Reconstr Surg, 2011; 127,Suppl 1:10S.
2.
AsaharaT, MasudaH, TakahashiT, KalkaC, PastoreC, SilverM, KearneM, MagnerM, IsnerJM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res, 1999; 85:221.
3.
KalkaC, MasudaH, TakahashiT, Kalka-MollWM, SilverM, KearneyM, LiT, IsnerJM, AsaharaT. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA, 2000; 97:3422.
4.
RealC, CaiadoF, DiasS. Endothelial progenitors in vascular repair and angiogenesis: how many are needed and what to do?Cardiovasc Hematol Disord Drug Targets, 2008; 8:185.
5.
AsaharaT, MuroharaT, SullivanA, SilverM, van der ZeeR, LiT, WitzenbichlerB, SchattemanG, IsnerJM. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997; 275:964.
RoncalliJG, TongersJ, RenaultMA, LosordoDW. Endothelial progenitor cells in regenerative medicine and cancer: a decade of research. Trends Biotechnol, 2008; 26:276.
PengLH, TsangSY, TabataY, GaoJQ. Genetically-manipulated adult stem cells as therapeutic agents and gene delivery vehicle for wound repair and regeneration. J Control Release, 2012; 157:321.
10.
SmadjaDM, CornetA, EmmerichJ, AiachM, GaussemP. Endothelial progenitor cells: characterization, in vitro expansion, and prospects for autologous cell therapy. Cell Biol Toxicol, 2007; 23:223.
11.
UrbichC, DimmelerS. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res, 2004; 95:343.
12.
FadiniGP, LosordoD, DimmelerS. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res, 2012; 110:624.
13.
BalajiS, VaikunthSS, LangSA, SheikhAQ, LimFY, CrombleholmeTM, NarmonevaDA. Tissue-engineered provisional matrix as a novel approach to enhance diabetic wound healing. Wound Repair Regen, 2012; 20:15.
14.
SchattemanGC, DunnwaldM, JiaoC. Biology of bone marrow-derived endothelial cell precursors. Am J Physiol Heart Circ Physiol, 2007; 292:H1.
15.
PeichevM, NaiyerAJ, PereiraD, ZhuZ, LaneWJ, WilliamsM, OzMC, HicklinDJ, WitteL, MooreMA, RafiiS. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 2000; 95:952.
16.
TianF, LiangPH, LiLY. Inhibition of endothelial progenitor cell differentiation by VEGI. Blood, 2009; 113:5352.
17.
AicherA, HeeschenC, Mildner-RihmC, UrbichC, IhlingC, Technau-IhlingK, ZeiherAM, DimmelerS. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med, 2003; 9:1370.
18.
De FalcoE, PorcelliD, TorellaAR, StrainoS, IachininotoMG, OrlandiA, TruffaS, BiglioliP, NapolitanoM, CapogrossiMC, PesceM. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood, 2004; 104:3472.
19.
DimmelerS, FlemingI, FisslthalerB, HermannC, BusseR, ZeiherAM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999; 399:601.
20.
HeissigB, HattoriK, DiasS, FriedrichM, FerrisB, HackettNR, CrystalRG, BesmerP, LydenD, MooreMA, WerbZ, RafiiS. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 2002; 109:625.
21.
IshidaY, KimuraA, KuninakaY, InuiM, MatsushimaK, MukaidaN, KondoT. Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. J Clin Invest, 2012; 122:711.
22.
HynesRO. The extracellular matrix: not just pretty fibrils. Science, 2009; 326:1216.
23.
CaiadoF, RealC, CarvalhoT, DiasS. Notch pathway modulation on bone marrow-derived vascular precursor cells regulates their angiogenic and wound healing potential. PLoS One, 2008; 3:e3752.
ChavakisE, AicherA, HeeschenC, SasakiK, KaiserR, El MakhfiN, UrbichC, PetersT, Scharffetter-KochanekK, ZeiherAM, ChavakisT, DimmelerS. Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med, 2005; 201:63.
27.
BouvardC, GafsouB, DizierB, Galy-FaurouxI, LokajczykA, Boisson-VidalC, FischerAM, HelleyD. Alpha6-integrin subunit plays a major role in the proangiogenic properties of endothelial progenitor cells. Arterioscler Thromb Vasc Biol, 2010; 30:1569.
28.
EhrbarM, MettersA, ZammarettiP, HubbellJA, ZischAH. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J Control Release: official journal of the Controlled Release Society, 2005; 101:93.
29.
SmadjaDM, BiecheI, HelleyD, LaurendeauI, SimoninG, MullerL, AiachM, GaussemP. Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6)J Cell Mol Med, 2007; 11:1149.
30.
ChoH, BalajiS, SheikhAQ, HurleyJR, TianYF, CollierJH, CrombleholmeTM, NarmonevaDA. Regulation of endothelial cell activation and angiogenesis by injectable peptide nanofibers. Acta Biomater, 2012; 8:154.
31.
ZhangSJ, ZhangH, WeiYJ, SuWJ, LiaoZK, HouM, ZhouJY, HuSS. Adult endothelial progenitor cells from human peripheral blood maintain monocyte/macrophage function throughout in vitro culture. Cell Res, 2006; 16:577.
GulatiR, JevremovicD, PetersonTE, ChatterjeeS, ShahV, VileRG, SimariRD. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res, 2003; 93:1023.
34.
BadorffC, BrandesRP, PoppR, RuppS, UrbichC, AicherA, FlemingI, BusseR, ZeiherAM, DimmelerS. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation, 2003; 107:1024.
35.
RoncalliJ, TongersJ, RenaultMA, LosordoDW. Biological approaches to ischemic tissue repair: gene- and cell-based strategies. Expert Rev Cardiovasc Ther, 2008; 6:653.
36.
SuhW, KimKL, KimJM, ShinIS, LeeYS, LeeJY, JangHS, LeeJS, ByunJ, ChoiJH, JeonES, KimDK. Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/macrophages and neovascularization. Stem Cells, 2005; 23:1571.
37.
GeorgescuA, AlexandruN, ConstantinescuA, TitorencuI, PopovD. The promise of EPC-based therapies on vascular dysfunction in diabetes. Eur J Pharmacol, 2011; 669:1.
KimKA, ShinYJ, KimJH, LeeH, NohSY, JangSH, BaeON. Dysfunction of endothelial progenitor cells under diabetic conditions and its underlying mechanisms. Arch Pharm Res, 2012; 35:223.
40.
CallaghanMJ, CeradiniDJ, GurtnerGC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal, 2005; 7:1476.
41.
MadonnaR, De CaterinaR. Cellular and molecular mechanisms of vascular injury in diabetes—part II: cellular mechanisms and therapeutic targets. Vascul Pharmacol, 2011; 54:75.
BurchfieldJS, DimmelerS. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair, 2008; 1:4.
44.
GordonA, KozinED, KeswaniSG, VaikunthSS, KatzAB, ZoltickPW, FavataM, RaduAP, SoslowskyLJ, HerlynM, CrombleholmeTM. Permissive environment in postnatal wounds induced by adenoviral-mediated overexpression of the anti-inflammatory cytokine interleukin-10 prevents scar formation. Wound Repair Regen, 2008; 16:70.
45.
KrishnamurthyP, RajasinghJ, LambersE, QinG, LosordoDW, KishoreR. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res, 2009; 104:e9.
46.
JuiHY, LinCH, HsuWT, LiuYR, HsuRB, ChiangBL, TsengWY, ChenMF, WuKK, LeeCM. Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-gamma, and indoleamine 2,3-dioxygenase. Cell Transplant, 2012; 21:971.
47.
KawamotoA, IwasakiH, KusanoK, MurayamaT, OyamadaA, SilverM, HulbertC, GavinM, HanleyA, MaH, KearneyM, ZakV, AsaharaT, LosordoDW. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation, 2006; 114:2163.
48.
ZhaoW, LiJJ, CaoDY, LiX, ZhangLY, HeY, YueSQ, WangDS, DouKF. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol, 2012; 18:1048.
49.
BurchfieldJS, IwasakiM, KoyanagiM, UrbichC, RosenthalN, ZeiherAM, DimmelerS. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res, 2008; 103:203.
50.
KrishnamurthyP, ThalM, VermaS, HoxhaE, LambersE, RamirezV, QinG, LosordoD, KishoreR. Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium. Circ Res, 2011; 109:1280.
